" class="no-js "lang="en-US"> Companies Archives - Page 2 of 2 - Medtech Alert
Saturday, September 13, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors

Sort by:

Date

Top Post

BioNTech and Regeneron Expand Strategic Collaboration to Advance Clinical Development of FixVac and Libtayo® (cemiplimab) Combination in NSCLC | Pharmtech Focus

BioNTech and Regeneron Expand Strategic Collaboration to Advance Clinical Development of FixVac and Libtayo® (cemiplimab) Combination in NSCLC

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced the expansion of its strategic collaboration […]

Read more

Companies

 Vygon acquires Macatt Medica

Vygon Acquires Macatt Medica, Peruvian Distributor of Single-use Medical Devices

Vygon, a specialist single-use medical devices group, today announces the acquisition of Macatt Medica, a […]

Companies

 NEC OncoImmunity Acquires VAXIMM's Neoantigen Vaccine Development Assets | Pharmtech Focus

NEC OncoImmunity Acquires VAXIMM's Neoantigen Vaccine Development Assets

NEC OncoImmunity (NOI), a subsidiary of NEC Corporation (NEC), and VAXIMM AG, a Swiss/German biotech […]

Companies

 BioEcho Life Sciences Receives Growth Equity Investment from Ampersand Capital Partners | Pharmtech Focus

BioEcho Life Sciences Receives Growth Equity Investment from Ampersand Capital Partners

BioEcho Life Sciences GmbH, an innovative manufacturer of nucleic acid purification solutions for molecular diagnostics […]

Companies

 Freenome Launches The Vallania Study For The Early Detection Of Multiple Cancers | Pharmtech Focus

Freenome Launches The Vallania Study For The Early Detection Of Multiple Cancers

Freenome, a privately held biotech company, today announced the initiation of Vallania, a clinical study […]

Companies

 Diadem Receives CE-IVD Certification to Market Its AlzoSure® Predict Prognostic Blood Test for the Early Prediction of Alzheimer's Disease in Europe | Pharmtech Focus

Diadem Receives CE-IVD Certification to Market Its AlzoSure® Predict Prognostic Blood Test for the Early Prediction of Alzheimer's Disease in Europe

Diadem Srl today announced CE IVD certification for its AlzoSure® Predict prognostic blood test for […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients

    Clinical Trials

     Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS

    Clinical Trials

     Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board

    Appointments

     Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera

    News

     Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic

    Clinical Trials

     Read more